Where Will Vertex Pharmaceuticals Be in 10 Years? | The Motley Fool

Jan 25, 2024 · Those who put money in Vertex Pharmaceuticals (VRTX-0.62%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period. …

CouponFollow Extension

62%
OFF

Where Will Vertex Pharmaceuticals Be In 10 Years? | The Motley Fool

3 weeks from now

Jan 25, 2024 · Those who put money in Vertex Pharmaceuticals (VRTX-0.62%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period. …

fool.com

03%
OFF

Where Will Vertex Pharmaceuticals Be In 10 Years? | The Motley Fool

3 weeks from now

Dec 4, 2023 · Vertex Pharmaceuticals (VRTX-0.03%) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing …

fool.com

31%
OFF

Where Will Vertex Pharmaceuticals Be In 10 Years? | The Motley Fool

3 weeks from now

Dec 18, 2022 · For a company like Vertex Pharmaceuticals (VRTX 5.31%), 10 years isn't a long time.The drug-development process takes between 12 and 14 years, on average, around 8 …

fool.com

$10
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? - Yahoo Finance

3 weeks from now

Jan 26, 2025 · This latest CF drug adds even more firepower to a franchise already set to rake in approximately $10.9 billion last year. With patents locked up into the 2030s and rivals nowhere …

yahoo.com

$10
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? - MSN

3 weeks from now

This latest CF drug adds even more firepower to a franchise already set to rake in approximately $10.9 billion last year. ... Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a ...

msn.com

$10
OFF

How Painkillers Could Be Vertex's Next $10 Billion Chapter

3 weeks from now

2 days ago · Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped. The company won Food and Drug …

investors.com

$8
OFF

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar ...

3 weeks from now

Jul 6, 2024 · Trikafta quickly became a blockbuster, and last year it generated $8.9 billion in revenue for Vertex. The company's other CFTR modulators made up the rest, for a total of …

yahoo.com

$10
OFF

Vertex Pharmaceuticals Has A $10 Billion Opportunity On The Table …

3 weeks from now

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Vertex Pharmaceuticals wasn't one of them. The 10 …

msn.com

$10
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? | The Motley Fool

3 weeks from now

Jan 26, 2025 · This latest CF drug adds even more firepower to a franchise already set to rake in approximately $10.9 billion last year. With patents locked up into the 2030s and rivals nowhere …

fool.com

$10
OFF

Vertex Pharmaceuticals Has A $10 Billion Opportunity On The …

3 weeks from now

Feb 6, 2024 · Alex Carchidi, The Motley Fool . ... In This Article: VRTX . Vertex Pharmaceuticals (NASDAQ: ... So for a few years now, the company's research and development ...

yahoo.com

57%
OFF

Where Will Vertex Pharmaceuticals Be In 10 Years? - Reportify

3 weeks from now

Vertex(VRTX) The Motley Fool · 2024-01-26 01:00. Those who put money in Vertex Pharmaceuticals (VRTX 0.57%) 10 years ago are sitting pretty right now. The company has …

reportify.cc

31%
OFF

Vertex Pharmaceuticals Just Won A Huge FDA Approval ... - The …

3 weeks from now

1 day ago · Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up …

fool.com

21%
OFF

Where Will Vertex Pharmaceuticals Be In 5 Years? | The Motley Fool

3 weeks from now

Oct 3, 2020 · Vertex Pharmaceuticals (VRTX 1.21%) is the blueprint for a growing pharmaceutical stock. Since it went public in 1991, the company has consistently increased revenue, …

fool.com

FAQs about Where Will Vertex Pharmaceuticals Be in 10 Years? | The Motley Fool Coupon?

Should you invest in Vertex Pharmaceuticals (VRTX) 10 years ago?

As the adage goes, winners keep winning. Those who put money in Vertex Pharmaceuticals ( VRTX 0.56%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period. However, a lot has changed for the biotech in the meantime, and as we all know, past success isn't a guarantee of anything. ...

What's going on with Vertex Pharmaceuticals?

Let's dig into what's going on with the biotech and determine where it might be in 10 years. In the past decade, Vertex Pharmaceuticals has made significant progress in treating cystic fibrosis (CF), a rare disease that damages people's internal organs. ...

Is Vertex Pharmaceuticals a good stock to buy?

That makes Vertex an excellent stock to buy and hold for a long while. Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. As the adage goes, winners keep winning. ...

Is Vertex Pharmaceuticals a Buy Now that the FDA approved?

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves from sending pain signals to the brain. ...

Does the Motley Fool recommend Vertex Pharmaceuticals?

The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ...

Will Vertex Pharmaceuticals add $1.5 billion in annual sales by 2030?

Adding around $1.5 billion in annual sales by 2030 would be a step in the right direction for Vertex Pharmaceuticals but this wouldn't be a transformative contribution. In November, the company reported third-quarter product sales that rose 12% year over year to an annualized $11.1 billion. ...